Founded in 1996, United Therapeutics is a biotech company based in Silver Spring, Maryland. The company's core mission is to develop innovative pharmaceuticals to treat life-threatening conditions, particularly vascular diseases like pulmonary hypertension and peripheral vascular disease. Their leading products include stable synthetic forms of prostacyclin, which are administered orally or subcutaneously. United Therapeutics aims to improve the quality of life for patients with severe medical conditions through cutting-edge medical solutions.
Notable figures associated with United Therapeutics include founder Martine Rothblatt, a prominent entrepreneur and advocate for medical innovation. The company has attracted significant investment from both private and institutional investors. Key achievements include FDA approval for several of their groundbreaking therapies and a strong pipeline of drugs in various stages of development. United Therapeutics has made a substantial impact on the biotech industry by providing effective treatments for previously underserved medical conditions, thereby enhancing patient outcomes globally.
